Literature DB >> 12604051

Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies.

J Szebeni1, L Baranyi, S Savay, J Milosevits, R Bunger, P Laverman, J M Metselaar, G Storm, A Chanan-Khan, L Liebes, F M Muggia, R Cohen, Y Barenholz, C R Alving.   

Abstract

Pegylated liposomal doxorubicin (Doxil) and 99mTc-HYNIC PEG liposomes (HPL) were reported earlier to cause hypersensitivity reactions (HSRs) in a substantial percentage of patients treated i.v. with these formulations. Here we report that (1) Doxil, HPL, pegylated phosphatidylethanolamine (PEG-PE)-containing empty liposomes matched with Doxil and HPL in size and lipid composition, and phosphatidylglycerol (PG)-containing negatively charged vesicles were potent C activators in human serum in vitro, whereas small neutral liposomes caused no C activation. (2) Doxil and other size-matched PEG-PE and/or PG-containing liposomes also caused massive cardiopulmonary distress with anaphylactoid shock in pigs via C activation, whereas equivalent neutral liposomes caused no hemodynamic changes. (3) A clinical study showed more frequent and greater C activation in patients displaying HSR than in non-reactive patients. These data suggest that liposome-induced HSRs in susceptible individuals may be due to C activation, which, in turn, is due to the presence of negatively charged PEG-PE in these vesicles.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12604051     DOI: 10.1081/lpr-120004790

Source DB:  PubMed          Journal:  J Liposome Res        ISSN: 0898-2104            Impact factor:   3.648


  41 in total

Review 1.  Immunological risk of injectable drug delivery systems.

Authors:  Wim Jiskoot; Rianne M F van Schie; Myrra G Carstens; Huub Schellekens
Journal:  Pharm Res       Date:  2009-02-27       Impact factor: 4.200

Review 2.  Nanoparticles and the immune system.

Authors:  Banu S Zolnik; Africa González-Fernández; Nakissa Sadrieh; Marina A Dobrovolskaia
Journal:  Endocrinology       Date:  2009-12-16       Impact factor: 4.736

Review 3.  Nanoparticle-mediated brain-specific drug delivery, imaging, and diagnosis.

Authors:  Hu Yang
Journal:  Pharm Res       Date:  2010-07-01       Impact factor: 4.200

4.  Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA.

Authors:  Jeremy D Heidel; Zhongping Yu; Joanna Yi-Ching Liu; Shyam M Rele; Yongchao Liang; Ryan K Zeidan; Douglas J Kornbrust; Mark E Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-22       Impact factor: 11.205

Review 5.  Safety Considerations of Cancer Nanomedicine-A Key Step toward Translation.

Authors:  Xiangsheng Liu; Ivanna Tang; Zev A Wainberg; Huan Meng
Journal:  Small       Date:  2020-05-14       Impact factor: 13.281

6.  Biomimetic nanovesicle design for cardiac tissue repair.

Authors:  Sruti Bheri; Jessica R Hoffman; Hyun-Ji Park; Michael E Davis
Journal:  Nanomedicine (Lond)       Date:  2020-08-05       Impact factor: 5.307

Review 7.  Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.

Authors:  Phatsapong Yingchoncharoen; Danuta S Kalinowski; Des R Richardson
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

8.  Biological evaluation of liposome-encapsulated hemoglobin surface-modified with a novel PEGylated nonphospholipid amphiphile.

Authors:  Vivek R Yadav; Okhil Nag; Vibhudutta Awasthi
Journal:  Artif Organs       Date:  2014-04-22       Impact factor: 3.094

Review 9.  Supra-molecular association and polymorphic behaviour in systems containing bile acid salts.

Authors:  Marco Calabresi; Patrizia Andreozzi; Camillo La Mesa
Journal:  Molecules       Date:  2007-08-07       Impact factor: 4.411

10.  Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience.

Authors:  Amy Y Grahn; Krystof S Bankiewicz; Millicent Dugich-Djordjevic; John R Bringas; Piotr Hadaczek; Greg A Johnson; Simon Eastman; Matthias Luz
Journal:  J Neurooncol       Date:  2009-05-24       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.